113 IL-6 inhibitors in hospitalised COVID-19 patients 5 fixed dose group would prevent one death at day 60. Length of stay Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.36 (-1.48 to 0.76) Low dose tocilizumab -3.05 (-4.30 to -1.79) Sarilumab 400mg -2.64 (-3.75 to -1.53) Supplementary Table 5. Multivariable linear regression analysis, differences in hospital LOS between the different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab 0.27 (-1.26 to 1.79) Low dose tocilizumab -2.79 (-4.55 to -1.03) Sarilumab 400mg -2.17 (-3.70 to -0.64) Supplementary Table 6. Multivariable linear regression analysis in patients who survived, differences in hospital LOS between the different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.40 (-1.65 to 0.85) Low dose tocilizumab -3.26 (-4.66 to -1.85) Sarilumab 400mg -3.00 (-4.24 to -1.76) Supplementary Table 7. Multivariable linear regression analysis in patients with a complete LOS, differences in hospital LOS between different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index
RkJQdWJsaXNoZXIy MTk4NDMw